neomycin

Neomycin (free base) is an antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C. It acts by inhibiting translation during protein synthesis.

Neomycin sulfate (Framycin sulfate) is a broad-spectrum aminoglycoside antibiotic that blocks the synthesis of bacterial proteins in order to exert antimicrobial activity. Neomycin sulfate is commonly used to screen prokaryotic and eukaryotic cells for Neo resistance genes.

Framycetin sulfate (Neomycin Sulphate B) belongs to aminoglycoside class of antibiotics that contain two or more aminosugars connected by glycosidic bonds.

Neomycin C hexaacetate is a tetracyclic antibacterial agent and the primary active isomer in the neomycin complex. Neomycin, an aminoglycoside containing 2-DOS, is composed of Neomycin A, Neomycin B, and Neomycin C.

Neomycin C, an isomeric component of the Neomycin complex, is a 2-DOS-containing aminoglycoside that comprises neomycin A, B, and C. It is notably less potent, exhibiting approximately half the activity of neomycin B [1] [2].

Neomycin sulfate (Standard) is the standard substance of Neomycin sulfate, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Neomycin sulfate (Framycin sulfate) is a broad-spectrum aminoglycoside antibiotic that blocks the synthesis of bacterial proteins in order to exert antimicrobial activity. Neomycin sulfate is commonly used to screen prokaryotic and eukaryotic cells for Neo resistance genes.

Paromomycin II is an aminoglycoside antibiotic that exhibits activity against both Gram-positive and Gram-negative bacteria, mycobacteria, and protozoa. It is particularly effective in treating amoebic dysentery and certain bacterial dysentery cases.

6"'-Deamino-6"'-hydroxyneomycin B is an aminoglycoside antibiotic produced by [Streptomyces fradiaeUC 75]. It is effective against both Gram-positive and Gram-negative bacteria and serves as an intermediate in the biosynthesis of neomycin.

Vineomycin A1 (OS-4742 A1) is an antibiotic effective against Gram-positive bacteria, identified in *Streptomyces matensis* subsp. vineus. It has also demonstrated antitumor activity in mice and holds potential for research in skin fibrosis.

Paromomycin binds specifically to the RNA oligonucleotide at the A site of bacterial 30S ribosomes, thereby causing misreading and premature termination of translation of mRNA and inhibition of protein synthesis followed by cell death. Paromomycin Sulfate (Aminosidine sulfate) is the sulfate salt form of paromomycin, a structural derivative of neomycin, an aminoglycoside antibiotic with amebicidal and bactericidal effects against predominantly aerobic gram-negative bacteria.

DMEA-PNU-159682 (molecule D12) is an ADC cytotoxin molecule that includes neomycin (MMDX) metabolites from liver microsomes and the effective ADC cytotoxin PNU-159682.

Framycetin is an aminoglycoside antibiotic and it also inhibits hammerhead ribozyme (Ki: 13.5 μM).

PNU-159682, a metabolite of anthracycline nemorubicin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity.

Paromomycin (Sulfate Salt) is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. Paromomycin in combination with sodium stibogluconate has proven to be effective in African and Indian VL (visceral leishmaniasis) and improves survival in African VL[3]. PS (Paromomycin Sulfate) is effective for elimination of B. coli without hematological side effects[4]. The activity of phosphoglucose isomerase was slightly inhibited by 10(-3) M paromomycin sulfate while those of hexokinase, phosphofructokinase and glucose-6-phosphate dehydrogenase were not inhibited[5]. In addition, with regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-aminohippurate clearance were significantly improved (P less than 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man[6]. Significantly higher frequencies of resistance to paromomycin, kanamycin, neomycin and tobramycin were observed in S. aureus isolates from PS (paromomycin supplemented) birds. Paromomycin supplementation resulted in resistance to aminoglycosides in bacteria of PS turkeys. Co-selection for resistance to other antimicrobial agents was observed in E. coli isolates[7].

Neamine, a broad-spectrum aminoglycoside antibiotic derived from Neomycin, exhibits potent antibacterial, antitumor, and neuroprotective activities. As an anti-angiogenesis agent, it specifically targets angiogenin [1] [2].

BDM88855 hydrochloride acts as a conformational inhibitor of the homologous AcrB protein. It enhances the antimicrobial activity of a range of antibiotics (such as benzylpenicillin, linezolid, and neomycin) against wild-type Escherichia coli.

BDM88855 is a conformational inhibitor of the homologous AcrB protein. This compound enhances the antibacterial effects of a range of antibiotics (such as: benzylpenicillin, linezolid, neomycin) against wild-type Escherichia coli.

Senfolomycin B exhibits activity against Gram-positive bacteria and mycobacteria, as well as effectiveness against penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-antibiotic-resistant Staphylococcus aureus. Additionally, Senfolomycin A demonstrates weaker activity against Gram-negative bacteria.

Paulomycin B exhibits activity against gram-positive bacteria and inhibits Staphylococcus aureus that is resistant to penicillin, streptomycin, neomycin, and macrolide antibiotics.

Paulomycin A2 exhibits antibacterial activity against Gram-positive bacteria and specifically inhibits Staphylococcus aureus that is resistant to penicillin, streptomycin, neomycin, and macrolide antibiotics.

Paulomycin A (Volonomycin A) exhibits antibacterial activity against Gram-positive bacteria, effectively inhibiting penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-resistant Staphylococcus aureus.

Senfolomycin A exhibits activity against Gram-positive bacteria and mycobacteria. It is also effective against penicillin-, streptomycin-, neomycin-, and macrolide-resistant Staphylococcus aureus. Additionally, Senfolomycin A has a weaker effect on Gram-negative bacteria.